Ginkgo Bioworks’ Q3 Woes Deepen Amid Shrinking Revenues and Persistent Cash Burn

Biotech platform company Ginkgo Bioworks has reported a disappointing third quarter, underscoring that the turnaround remains elusive. Total revenue for Q3 plunged to roughly $39 million, down 56% year‑over‑year—even after adjusting for a prior‑year $45 million non‑cash deferred revenue boost. In its core Cell Engineering segment, revenue fell to about $29 million, while the Biosecurity division clocked in around $9 million. Adjusted EBITDA came in negative at $56 million, and a net loss of about $81 million was reported. On the upside, Ginkgo ended the quarter with a cash, cash‑equivalents and marketable securities balance of roughly $462 million, a buffer for now. All things considered: revenue deceleration coupled with heavy cash burn has investors on edge and the stock under pressure. #GinkgoBioworks #SyntheticBiology #BiotechEarnings #CashBurn #SlimScan #GrowthStocks #CANSLIM